The CASP9 knockout 769-P polyclonal cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population targeting the human CASP9 gene in the 769-P renal cell carcinoma line. This product provides a heterogeneous pool of edited cells, each carrying targeted disruptions in the CASP9 locus, enabling loss-of-function studies without the bottleneck of single-cell cloning. The polyclonal format preserves genetic diversity, making it suitable for experiments where clonal variation could confound results. Researchers can use these cells to ablate CASP9 expression, a key initiator caspase of the intrinsic apoptosis pathway.
The parental 769-P cell line was originally derived from a primary renal adenocarcinoma of clear cell histology, making it a well-characterized in vitro model for clear cell renal cell carcinoma (ccRCC). 769-P cells retain key features of ccRCC, including VHL pathway dysregulation, and are widely used to study tumor biology, drug responses, and apoptotic signaling in renal cancer. The knockout background provides a clean system to interrogate CASP9-dependent mechanisms in a disease-relevant context.
CASP9 encodes caspase-9, the initiator caspase of the mitochondrial apoptosis pathway. Upon apoptotic stimuli, cytochrome c released from mitochondria binds APAF1 to form the apoptosome, which recruits and activates caspase-9. Active caspase-9 cleaves executioner caspases CASP3 and CASP7, which process substrates like PARP1 and DFFA/ICAD, leading to DNA fragmentation. Upstream regulators BAX and BAK promote cytochrome c release, while BCL2 inhibits it; SMAC/DIABLO counters XIAP-mediated suppression of caspases. HSP70 interacts with the apoptosome, modulating activation. Thus, CASP9 integrates mitochondrial damage signals into the execution phase of apoptosis.
In renal cell carcinoma, apoptosis dysregulation is a hallmark of tumor development and chemoresistance. The 769-P CASP9 knockout polyclonal cells allow dissection of apoptotic signaling downstream of mitochondrial outer membrane permeabilization, providing a tool to assess the dependency of ccRCC cells on the intrinsic apoptosis pathway. These cells can reveal how loss of CASP9 affects sensitivity to chemotherapeutic agents or targeted therapies that induce mitochondrial stress, such as BH3 mimetics. Moreover, they facilitate studies on alternative cell death mechanisms that may compensate for caspase-9 deficiency.
Key research applications include apoptosis resistance studies, where the cells can be challenged with staurosporine or other apoptotic inducers, followed by annexin V apoptosis assays or caspase-3/7 activity measurements to confirm functional knockout. Western blotting for cleaved caspase-9 and its downstream targets validates loss of signal propagation. Drug sensitivity assays, such as MTT-based viability tests, can identify compounds whose efficacy depends on intact apoptotic machinery. Additionally, these cells are valuable for generating isogenic comparisons when paired with the parental line, enabling precise functional genomics studies. For further inquiries about this product, please contact Ascent Research.
